# Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

> **NCT02287727** · PHASE2 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Rectal Adenocarcinoma
- Stage IIA Rectal Cancer
- Stage IIB Rectal Cancer
- Stage IIC Rectal Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Rectal Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02287727
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-03
- **Primary completion:** 2016-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287727, "Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02287727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*